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Preamble
Media coverage of amblyopia treatment has high-
lighted instances where children aged between 7 
and older,1–3 newly diagnosed with amblyopia 
through community eyecare services, were deemed 
‘too old’ to effectively respond to conventional 
amblyopia treatment beyond refractive error cor-
rection. Conventional amblyopia treatment usu-
ally comprises this correction followed by a 
18-week refractive adaptation period,4 then 
engagement with occlusion or atropine/optical 
penalisation to treat any residual amblyopia.5 
While isolated cases, at odds with Royal College of 
Ophthalmologists recommendations6 and College 
of Optometrists information materials3,7 regarding 
amblyopia treatment, they do highlight that formal 
guidance from these professional bodies about bin-
ocular vision anomalies8,9 does not specifically 
make reference to a child’s age beyond stating the 
importance of early diagnosis and treatment of 
strabismus/amblyopia. Such cases occurring within 
the community eyecare sphere would suggest that 
it is worth revisiting the literature on the subject of 
amblyopia treatment in older children (aged 7 and 
above, as defined by media coverage1–3 and classi-
fication by seminal Paediatric Eye Disease 
Investigator Group (PEDIG) research10–12 or other 
work),13,14 to address such misconceptions.
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Abstract: In recent years, media coverage has demonstrated instances in which families of 
children aged 7 and older, newly diagnosed with strabismic and/or anisometropic amblyopia 
through community eyecare services, were told it was ‘too late’ for their child to effectively 
respond to conventional amblyopia treatment (occlusion or atropine penalisation). Formal 
guidance pertaining to binocular vision anomalies from eyecare professional bodies does not 
specifically make reference to a child’s age, beyond stating the importance of early diagnosis 
and treatment of strabismus/amblyopia. However, there have been many changes in the way 
we view the recovery period for amblyopia, and it is well demonstrated both within literature 
and clinical practice that conventional treatment can improve amblyopic eye visual acuity in 
children beyond the age of 7 years. The occurrence of these media described cases within 
the community eyecare sphere would suggest it is worthwhile revisiting the literature on the 
subject of amblyopia treatment in older children (aged 7+ years), to address misconceptions 
and place in the spotlight current considerations facing clinicians when treating newly 
diagnosed amblyopia within this age group. This perspective review provides an evidence-
based update covering the various considerations associated with treatment of amblyopia in 
older children, along with recent amblyopia treatment advances that could have an impact 
on treatment prospects for this patient group. Considerations include the risks, benefits 
and efficacy of treating newly diagnosed amblyopia in older children, monitoring density of 
suppression to mitigate intractable diplopia risk, and recent findings regarding binocular 
treatments for amblyopia.
Keywords: amblyopia, atropine penalisation, density of suppression, occlusion therapy, older 
children perceptual learning
Received: 14 January 2019; revised manuscript accepted: 17 May 2019.
Correspondence to:  
Marianne E.F. Piano  
School of Health Sciences, 
University of Surrey, 
Guildford, Surrey GU2 
7XH, UK
m.coleman@surrey.ac.uk
Marianne E.F. Piano  
School of Health Sciences, 
University of Surrey, 
Guildford, UK
Anita J. Simmers  
Department of Vision 
Sciences, School of Health 
and Life Sciences, Glasgow 
Caledonian University, 
Glasgow, UK
857379 OED0010.1177/2515841419857379Therapeutic Advances in OphthalmologyMEF Piano and AJ Simmers
research-article20192019
Perspective
Therapeutic Advances in Ophthalmology 11
2 journals.sagepub.com/home/oed
How often is amblyopia newly diagnosed in 
older children?
There is little data on the incidence of late diag-
nosis of amblyopia in the United Kingdom, as 
well as limited data on amblyopia prevalence in 
older children aged 7 and above.15 However, 
some degree of inference can be made using pri-
mary vision screening audit data from the British 
and Irish Orthoptic Society,16 which suggests 
that from 42 screening sites across the United 
Kingdom and Northern Ireland, 7% of children 
eligible for screening failed to attend in the 2016–
2017 school year (n = 12,539 of 175,407) and 
from 38 of these sites, 29% of children, on aver-
age, fail vision screening but then do not attend 
for follow-up (mean n = 3182 of 10,974, non-
attendance range 5–73%). Based on prevalence 
of past/present amblyopia at age 7 from a UK 
regional birth cohort of 7825 children (3.6%),15 
a rather crude estimate is that up to 578 children 
across these 42 sites each year may present at a 
community eyecare service in future with 
untreated amblyopia of some degree, although it 
is impossible to determine if/when this presenta-
tion will occur, and therefore a diagnosis rate. 
This assumes 16,056 children not attending ini-
tial screening or failed screening follow-ups16 and 
tallies against some dated regional UK studies 
identifying that 0.28–3%17,18 of children having a 
vision assessment after age 7 may be newly diag-
nosed with amblyopia. A similar level was 
reported in Australia among 12-year-old children 
(0.21%).19 While a dearth of literature in this 
area limits accuracy of these inferences, and soci-
odemographic factors influencing amblyopia 
risk15 and uptake of vision screening20,21 or UK 
National Health Service-funded optometric sight 
tests20–22 should be considered, it is reasonable to 
suggest that a relatively low number of older chil-
dren (7 and above) may be newly diagnosed with 
amblyopia in the United Kingdom each year.
Given this posited low figure, it is hardly surpris-
ing that optometry practice patterns regarding 
advice given to families of an older child newly 
diagnosed with amblyopia appear to vary, and at 
times contradict guidance from professional bod-
ies. Indeed, Shah and colleagues23 point out that 
it is difficult for the practicing optometrist to gain 
experience in paediatric optometry generally, due 
to the infrequent attendance of young children 
within practice.24 It is therefore important to con-
sider the impact of such contradictions against 
existing guidance.
What happens if amblyopia is not treated?
Untreated amblyopia in school-aged children 
can impact in a number of ways, from fine visuo-
motor task difficulties associated with reduced/
absent binocular vision,25–27 to lower self-esteem 
or self-perception28,29 and other psychosocial 
domains,30 to limitations on educational attain-
ment28,31,32 (although for an earlier birth cohort 
this was not the case).33 In adulthood, lifelong 
bilateral visual impairment risk is increased by 
1.2–3.3% where dense amblyopia is present.34 
The numbers quoted above for older children 
newly diagnosed with amblyopia may seem small 
when considering orthoptic throughput of 
younger children, but current evidence and the 
practice guidelines drawing upon it emphasises 
the importance of, at a minimum, initiating treat-
ment in older children to reduce these impacts. 
Optical correction alone, while thought to pro-
duce some degree of improvement in amblyopic 
eye visual acuity, appears to be insufficient to 
resolve the full amblyopic visual acuity defect in 
older children,12,35,36 and while occlusion treat-
ment is not without psychosocial impacts of its 
own,29,37–40 it can be seen that there are more 
benefits to treatment than just improvement of 
visual acuity and binocular function. However, 
conventional amblyopia treatment (occlusion, 
atropine) for this group may not be without risk, 
which should also be considered.
What are the risks associated with treating 
amblyopia using occlusion or atropine in 
older children?
Clinically, the primary reason for some degree of 
nervousness when treating amblyopia in older chil-
dren is the risk of intractable diplopia. Intractable 
diplopia has a significant impact on visual function 
and wellbeing41–43 and is difficult to remedy in 
older children,44 remaining a highly undesirable 
complication of amblyopia treatment. This can 
arise through alteration of corticoretinal suppres-
sion during treatment, and it is recommended that 
density of this suppression be monitored when 
treating strabismic and mixed strabismic/anisome-
tropic amblyopia in children over 5 years of age, as 
a measure of intractable diplopia risk.45 Incidence 
of intractable diplopia following amblyopia treat-
ment with occlusion or atropine remains extremely 
low in the United Kingdom,46,47 perhaps because 
of our highly conservative approach to amblyopia 
treatment in older children,46 but is the evidence 
base for this approach valid?
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Concerns regarding intractable diplopia can affect 
treatment approaches for older children. A survey 
of UK orthoptists found they were less likely to 
use atropine penalisation with this age group,48 
with risk of systemic side effects or intractable 
diplopia highlighted as key concerns. This is 
despite reported side effects being few within the 
survey, systemic retention of atropine being 
thought to reduce with age,49 and the absence of 
nationwide yearly incidence data for systemic 
atropine side effects or intractable diplopia to evi-
dence such concerns.
Furthermore, major question marks hang over 
the test–retest reliability of the tools we use to 
measure suppression density,50–53 and the validity 
of the rather arbitrary suppression density cutoffs 
used in practice to aid clinical decision-making 
about stopping treatment due to unacceptable 
diplopia risk.46,52 In addition, no studies currently 
demonstrate a relationship between age and den-
sity of suppression in amblyopia,50,52,53 nor rein-
force the idea that density of suppression is more 
easily disrupted in older children. In fact, sup-
pression in recent years has been painted as the 
‘enemy of successful amblyopia treatment’,54 and 
a widely cited PEDIG study exploring amblyopia 
treatment with occlusion and atropine for older 
children did not measure suppression density,12 
reporting incidents of diplopia were infrequent 
and short-lived. It is therefore difficult to argue 
whether treating newly diagnosed amblyopia in 
older children carries significantly elevated risk of 
intractable diplopia.
Should we continue to rely on density of suppres-
sion measurements for intractable diplopia risk 
assessment and clinical decision-making during 
amblyopia treatment for older children? Without 
comparable incidence data on intractable diplo-
pia in other parts of the world, it is difficult to 
determine whether the UK’s virtually non- 
existent incidence of intractable diplopia post-
amblyopia treatment47 originates purely from our 
zealous monitoring of suppression density. With a 
lack of evidence generally on the nature of changes 
in suppression density for older children during 
both occlusion and atropine penalisation treat-
ments for amblyopia, discontinuing the practice 
is as difficult to justify as continuing it.
More research in these areas, as well as audit data 
on incidence of early termination of amblyopia 
treatment due to suppression changes, could sta-
bilise the foundations for density of suppression 
monitoring practices when embarking upon 
amblyopia treatment for older children, to max-
imise treatment benefit. Importantly, current evi-
dence shows there is no clinical justification for 
refusing to offer treatment to a newly diagnosed 
older child, provided appropriate monitoring is 
employed. However, visual acuity and binocular 
function gains for older children during amblyo-
pia treatment may be more limited. This is an 
issue warranting further examination.
How effective is amblyopia treatment for 
older children?
It is widely accepted that treatment for moderate 
and severe strabismic and/or anisometropic 
amblyopia can produce better visual outcomes 
when it is the first treatment attempt with occlu-
sion or atropine, compared to instances where 
treatment has been attempted in the past.10–12 In 
addition, it is acknowledged that treatment effec-
tiveness can reduce with age for both treated10 
and untreated amblyopia,10,13,55 although not all 
of these studies included children treated with 
atropine penalisation.13,55 These findings have 
influenced amblyopia treatment guidelines from 
both the College of Optometrists and the Royal 
College of Ophthalmologists, which state that 
treatment is more effective when initiated earlier.
However, many seminal studies from the PEDIG 
cited here are affected by restrictive inclusion cri-
teria and definition of treatment responder, and a 
fixed occlusion dosage for duration of treatment 
prior to being defined as a responder/non-
responder. Furthermore, comparisons between 
the treatment and control groups in key papers 
focusing on older children were affected by use of 
optical correction as the control condition, now 
known to produce a treatment effect.56 These 
aspects of older Amblyopia Treatment Study pro-
tocols limit applicability of findings to a rather 
specific set of instances not always reflective of 
clinical practice, and PEDIG authors have rec-
ommended in other papers to always attempt 
treatment in older children regardless of previous 
treatment history.10,56–58 Indeed, recent studies 
from Fronius and colleagues55 suggest interocular 
acuity difference improvements with occlusion of 
43% on average for untreated amblyopes aged 7 
and above. A later PEDIG study also found 
increasing occlusion dosage produced further 
acuity improvements in a sample of children with 
residual amblyopia that included 38 children 
aged 7+ years.57 Further study of the impact of 
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applying a stepped conventional treatment 
approach for strabismic and/or anisometropic 
amblyopia (including atropine as well as occlu-
sion) in older children could therefore be 
beneficial.
Overall, the literature would seem to indicate that 
with good compliance, appropriate monitoring of 
suppression density, and suitable tailoring of 
occlusion dosage, initiating treatment for strabis-
mic and/or anisometropic amblyopia should the-
oretically maximise the acuity of the amblyopic 
eye. However, even with good compliance, there 
are instances where amblyopia does not fully 
resolve, and a residual interocular acuity differ-
ence remains. Patient characteristics that differ-
entiate responders and non-responders to 
conventional amblyopia treatment are still not 
well understood, but current evidence demon-
strates that age at start of treatment is not a sole 
diktat for either occlusion10–13,55 or atropine.10–12 
This raises the question of whether we are yet to 
identify the most effective combination of ambly-
opia treatment approaches for this group, and 
whether newer amblyopia therapies may have 
potential to minimise or address a residual 
interocular acuity deficit.
Will newer, binocular treatments for 
amblyopia be more effective in older 
children?
More recently, amblyopia has come to be regarded 
as a binocular condition, due to the known defi-
cits occurring in the fellow eye59–67 and the role 
of  defective binocular vision as an amblyogenic 
factor.68 Emerging amblyopia treatments have 
embraced this, utilising stereoscopic presentation 
techniques and luminance/contrast matching to 
promote binocular combination of the amblyopic 
and fellow eye.69,70 Some of the most well-known 
studies demonstrating the use of these emerging 
treatments with older children and adults are the 
works of Levi, Li and colleagues, who successfully 
employed monocular or binocular perceptual 
learning techniques to reduce interocular acuity 
difference in children71–73 and adults74–76 aged 
7–17 years.
The majority of participants in these studies has a 
history of previous amblyopia treatment or at a 
minimum have undergone refractive adaptation, 
and it has proved difficult to explain individual dif-
ferences in treatment outcomes and dose–response 
curves between participants.77,78 The efficacy of 
such binocular treatments as a first-line amblyopia 
therapy is yet to be established, although trials are 
underway. However, given existing evidence sug-
gests better conventional treatment outcomes 
(atropine/occlusion) in children with no history of 
previous amblyopia treatment, it seems reasonable 
to suggest emerging, binocular amblyopia treat-
ment approaches could have a similar enhanced 
impact where used as a first-line treatment. 
Whether these techniques are more effective at 
resolving an interocular acuity difference for newly 
diagnosed older children, in comparison to con-
ventional treatment approaches, is also an area 
worth exploring.
Despite being designed to circumnavigate con-
ventional suppression mechanisms to promote 
binocular combination, these emerging therapies 
have not resulted in instances of intractable diplo-
pia79–81 and appear not to disrupt suppression,82 
but it is important to note that treatment dura-
tions were limited to 1 h a day, compliance in 
many of these trials has been limited,79,82 and 
suppression measures used may not necessarily 
correlate with conventional density of suppres-
sion measurement techniques such as the Bagolini 
Filter Bar, and as such may not tap into the same 
mechanisms of suppression.83
Our own randomised controlled trial,84 involving 
children with residual amblyopia aged 5–14 years, 
compared contrast-balanced binocular amblyopia 
treatment with monocular and non-contrast- 
balanced binocular approaches, using a stereo-
scopic child-friendly first-person shooter para-
digm85 to promote replayability. Although the 
trial terminated prematurely due to limited 
recruitment associated with use of an office-based 
treatment paradigm, we found changes in density 
of suppression as measured with the Bagolini 
Filter Bar during the treatment period. This 
resulted in termination of treatment before the 
end of the 10-day treatment period for 4 of 14 
children, scattered across all three viewing modal-
ities (contrast-balanced, monocular, non-contrast 
balanced), with reduction in suppression from 
baseline ranging from four to nine filters.
While these numbers are small and preclude for-
mal analysis, they demonstrate that suppression 
density as measured clinically can change during 
stereoscopically administered amblyopia treat-
ment paradigms. When interpreting data regard-
ing diplopia risk in association with binocular 
amblyopia treatments, that utilise stereoscopic 
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viewing for differential presentation, some degree 
of caution may be required. As research in this 
new area continues, more evidence is likely to 
emerge regarding the nature of any changes in 
suppression that may occur with this treatment, 
and whether first-line deployment of these thera-
pies for older children carries the same risks (if 
any) as conventional amblyopia treatment. If not, 
this could open up an important access avenue 
for older children newly diagnosed with amblyo-
pia, which practitioners in the community need to 
be aware of.
Conclusion
Current conventional amblyopia treatment guide-
lines stating better outcomes can be achieved in 
younger children are based on up to date litera-
ture and standard treatment approaches, defined 
previously as refractive error correction, refractive 
adaptation and use of occlusion or atropine 
penalisation to treat residual amblyopia. It is not 
possible to conclude from existing evidence that a 
newly diagnosed older child is as likely to have a 
good visual outcome from conventional amblyo-
pia treatments as a child who is younger, even 
when considering the differential effects of com-
pliance and previous amblyopia treatment 
history.
However, a growing body of evidence supports 
the efficacy of many emerging binocular amblyo-
pia therapies, where compliance is good. Due to 
the relatively small numbers of older children 
diagnosed with amblyopia each year, it would be 
logistically challenging to evaluate and compare 
first-line treatment effects for these emerging 
therapies against conventional treatments. Yet 
work in this area, even if conducted over a pro-
tracted period of time, could be informative in 
determining which patient groups maximally 
benefit from these approaches, and whether they 
carry the same perceived risks as conventional 
treatment approaches with regard to changes in 
density of suppression.
Nonetheless, the evidence does show that it is 
always worth attempting amblyopia treatment for 
older children as many can and will experience an 
improvement in visual function. Essentially, the 
words ‘It’s too late’ should not be something par-
ents have to hear as part of receiving an amblyo-
pia diagnosis for their older child. The authors 
hope this article will equip eyecare professionals 
to have a balanced discussion with parents about 
the risks and benefits of amblyopia treatment for 
older children and take an evidence-based 
approach to managing amblyopia arising in this 
group.
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